CGC

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced that, due to the requisite quorum not being present, its Annual General and Special Meeting of shareholders (the “Meeting”), scheduled for Friday, September 25, 2026, at 1:00 p.m. ET via live webcast, was convened and then adjourned. The Meeting will reconvene on Friday.

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced it has extended the proxy voting deadline for its upcoming Annual General and Special Meeting of shareholders (the “Meeting”) to 12:00 p.m. ET on Friday, September 25, 2026. The Meeting will be held later the same day, at 1:00 p.m. ET via live audio webcast at www.virtu.

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced that it will supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom (the “UK”), expanding the reach of its international cannabis business into another European market. The Canadian-grown flower strains will be supplied to GROW.

In the latest trading session, Canopy Growth Corporation (CGC) closed at $0.94, marking a +2.57% move from the previous day.

Canopy Growth (CGC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Canopy Growth Corporation (CGC) reached $0.94 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today reminds shareholders to vote ahead of its Annual General and Special Meeting of shareholders (the “Meeting”) scheduled for Friday, September 25, 2026, at 1:00 p.m. ET. To ensure their votes are counted at the Meeting, shareholders should submit their vote no later than 1:00 p.m.

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges.

The cannabis industry is entering September, and investors are once again searching for opportunities across the sector. After years of volatility, several marijuana companies are showing signs of stronger financial performance. Revenue is improving for some operators. Meanwhile, others are cutting costs, strengthening margins, and expanding internationally. That combination could put marijuana stocks back on investors' radar. However, this is no longer simply a story about rapid expansion. Investors are becoming more selective about which cannabis companies deserve their attention. Today, profitability matters. Cash flow matters. Additionally, investors want companies with strong brands and opportunities beyond their existing markets. International cannabis growth has become particularly important. Europe continues expanding its medical cannabis industry. As a result, Canadian producers are positioning themselves to capture growing international demand. Meanwhile, the United States remains an important potential catalyst. Changes to federal cannabis regulations could eventually reshape the industry's investment landscape.

Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.